Diabetes Management
Pioglitazone in Combination with Insulin—An Overview of Results from PROactive
Bernard Charbonnel, MD Professor of Endocrinology and Metabolic Diseases, University of Nantes and Department of Internal Medicine, Endocrinology and Diabetes, Hôtel Dieu, University Hospital of Nantes
Abstract
Pioglitazone provides one of several add-on therapy options for patients with unsatisfactory glycemic control treated with insulin. Although pioglitazone has the beneficial feature of low hypoglycemia risk, it has an overlapping adverse event profile with insulin in terms of edema (with the potential to exacerbate heart failure) and weight gain, leading to possible concern over their use in combination. Fortunately, subgroup analyses from the Prospective pioglitazone clinical trial in macrovascular events (PROactive) have provided valuable insights into the efficacy and safety profile of pioglitazone in patients on established insulin therapy. Pioglitazone improved glycemic control and lipids, while enabling patients to reduce their insulin requirements. With the combination, edema and weight were predictable with no excess exacerbation of heart failure. Importantly, pioglitazone had a good macrovascular safety profile (with a trend toward benefit), consistent with the overall population. This article provides an overview of the results from the insulin-treated subgroup in PROactive and highlights some of the clinical implications for pioglitazone–insulin combination therapy.
Keyword Type 2 diabetes, pioglitazone, insulin, glycemic control, tolerability, safety, edema, weight gain, heart failure, cardiovascular disease, outcomes
Disclosure: Bernard Charbonnel, MD, was a member of the PROactive Executive Committee and has received fees for consultancy, speaking, travel, and accommodation from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck, Sharpe & Dohme, Novartis, Novo Nordisk, Roche, sanofi-aventis and Takeda. Received: January 11, 2011 Accepted: March 21, 2011 Citation: US Endocrinology, 2011;7(2):110–5 Correspondence: Bernard Charbonnel, MD, Clinique d’Endocrinologie, Maladies Métaboliques et Nutrition, CHU de Nantes, Hôtel Dieu, 1 place Alexis Ricordeau, 44093 Nantes Cedex 1, France. E:
bernard.charbonnel@
univ-nantes.fr
Many patients with type 2 diabetes require insulin therapy during the course of their disease, either as monotherapy or as an addition to existing oral glucose-lowering therapy.1–3
be sufficient to maintain adequate glycemic control, and additional therapies might therefore be required.1–3
Randomized controlled trials (RCTs) have shown
However, this might not always The oral glucose-lowering drug
pioglitazone is one of several options available for add-on therapy in patients whose glycemic control remains unsatisfactory on insulin treatment regimens.2–7
that pioglitazone provides significant improvements in glycemic control and lipid profile in insulin-treated patients with type 2 diabetes.8–13
In one
recent meta-analysis of four efficacy/safety RCTs, the addition of pioglitazone to insulin therapy provided a 1.22 % reduction in glycated
hemoglobin (HbA1c) from baseline, as well as a 1.63 mmol/l improvement in fasting plasma glucose, a 0.21 mmol/l improvement in high-density lipoprotein (HDL) cholesterol, and a 0.05 mmol/l improvement in triglycerides.13
The main adverse events associated
with pioglitazone in these insulin-treated patients included edema, weight gain, and hypoglycemia.12,13
Edema and weight gain are
well-characterised adverse events associated with pioglitazone use regardless of background therapy, whereas pioglitazone use per se is generally associated with a low risk of hypoglycemia.14,15
Improved 110
glycemic control provided by pioglitazone probably contributes to any increased risk of insulin-induced hypoglycemia and, at least to some extent, weight gain.14,15
The Prospective pioglitazone clinical trial in macrovascular events (PROactive) was a landmark cardiovascular (CV) outcomes study looking at the impact of pioglitazone on macrovascular endpoints in high-CV-risk patients with type 2 diabetes.16,17
Since publication of the
main results in 2005, PROactive has continued to provide a wealth of information on the CV safety/efficacy profile and metabolic effects of pioglitazone via a range of predefined and post-hoc analyses.17–28 Recently, several analyses have looked specifically at the subgroup of patients entering the study on insulin therapy, thus adding considerably to the existing data set on pioglitazone–insulin combination therapy.26–28
This article provides an overview of the key metabolic effects, impact on CV outcomes, and safety/tolerability profile of pioglitazone among insulin-treated patients in PROactive and briefly discusses the clinical implications of these findings. Relevant publications were identified via PubMed searches using the terms ‘pioglitazone AND insulin AND (combination OR addition OR concomitant OR proactive)’.
© TOUCH BRIEFINGS 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84